In January 2017, a team from Essential Biotechnology was invited to present to the Wellcome Trust Translation Fund Committee in London, UK. Drs. Clarke and James gave an overview of Essential’s scientific and clinical development programs related to anti-CRR9 cancer therapeutics. The team represented one of a handful of programs worldwide that were invited to present. Thanks to the Trust for their support of anti-CRR9 feasibility studies and the opportunity to visit them.